CA Patent

CA3099287A1 — Solid forms of an fgfr inhibitor and processes for preparing the same

Assigned to Incyte Corp · Expires 2019-11-07 · 7y expired

What this patent protects

The present disclosure relates to solid forms and polymorphs of compound (1): 3-(2,6-difluoro-3,5-dimethoxyphenyl) -l-ethyl-8-(morpholin-4-ylmethyl)-l,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one, methods of preparation thereof, and intermediates in the prep…

USPTO Abstract

The present disclosure relates to solid forms and polymorphs of compound (1): 3-(2,6-difluoro-3,5-dimethoxyphenyl) -l-ethyl-8-(morpholin-4-ylmethyl)-l,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.

Drugs covered by this patent

Patent Metadata

Patent number
CA3099287A1
Jurisdiction
CA
Classification
—
Expires
2019-11-07
Drug substance claim
No
Drug product claim
No
Assignee
Incyte Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.